menu
    • menu
    [{"orgOrder":0,"company":"Biomerieux","sponsor":"Biomerieux","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Polyferon","moa":"Interferon gamma receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biomerieux","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomerieux \/ Biomerieux","highestDevelopmentStatusID":"10","companyTruncated":"Biomerieux \/ Biomerieux"},{"orgOrder":0,"company":"Biomerieux","sponsor":"Biomerieux","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Virus-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"TTV DNAemia","moa":"TTV DNAemia","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Biomerieux","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomerieux \/ Biomerieux","highestDevelopmentStatusID":"1","companyTruncated":"Biomerieux \/ Biomerieux"},{"orgOrder":0,"company":"Biomerieux","sponsor":"Biomerieux","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Biomerieux","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomerieux \/ Biomerieux","highestDevelopmentStatusID":"1","companyTruncated":"Biomerieux \/ Biomerieux"},{"orgOrder":0,"company":"Biomerieux","sponsor":"Biomerieux","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Biomerieux","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomerieux \/ Biomerieux","highestDevelopmentStatusID":"1","companyTruncated":"Biomerieux \/ Biomerieux"}]

    Find Clinical Drug Pipeline Developments & Deals by Biomerieux

    Menu

    Biomerieux

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Biomerieux

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Biomerieux

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TTV DNAemia

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Recipient : Hospices Civils de Lyon

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TTV-based mAnagement Of Long-term ImmunosuppreSsion in Kidney Transplantation

                            Details : TTV DNAemia is a Virus-drug Conjugate drug candidate, which is currently being evaluated in clinical studies for the treatment of Infections.

                            Product Name : Undisclosed

                            Product Type : Virus-drug Conjugate

                            Upfront Cash : Inapplicable

                            February 17, 2025

                            Lead Product(s) : TTV DNAemia

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Recipient : Hospices Civils de Lyon

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Biomerieux

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Biomerieux

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Recipient : Hospices Civils de Lyon

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Immune Response to Vaccinations in Hematopoietic Stem Cell Transplant Recipients

                            Details : This drug candidate is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 06, 2018

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Recipient : Hospices Civils de Lyon

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Biomerieux

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Biomerieux

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Recipient : University Hospital, Geneva

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Impact of the Lab-score on Antibiotic Prescription Rate in Children With Fever Without Source

                            Details : This drug candidate is currently being evaluated in clinical studies for the treatment of Fever.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 01, 2014

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Recipient : University Hospital, Geneva

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Biomerieux

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Biomerieux

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Polyferon

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : Radboud University Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy of Interferon-gamma in Combination With Anidulafungin for the Treatment of Candidemia

                            Details : Interferon Gamma is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Candidemia.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            January 05, 2011

                            Lead Product(s) : Polyferon

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : Radboud University Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth